Peters / Besse New Therapeutic Strategies in Lung Cancers

1. Auflage 2014
ISBN: 978-3-319-06062-0
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 255 Seiten, eBook

This book provides an up-to-date review of current management techniques for Non-Small Cell Lung Cancer. It addresses all of the latest issues that have been raised by the discovery of oncogenic drivers and the improvement of diagnosis and therapeutic methods, including new radiotherapy techniques and anticancer strategies like immunotherapy. New strategies for patients with molecular alterations and the management of particular types of cases are also highlighted. Written by recognized experts in their field, the book represents a unique and valuable resource in the field of lung cancer, both for those currently in training and for those already in clinical or research practice.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Peters, Solange

Besse, Benjamin

Inhaltsverzeichnis

Preface.- Foreword.- Screening.- New Diagnostic Approaches.- PET and Staging Minimally Invasive (EBUS).- Innovative Approaches in Early NSCLC.- Minimally Invasive Surgery for Early NSCLC.- Stereotaxic Radiotherapy in Localized Cancer.- How to Personalize Perioperative Chemotherapy in Early Cancer ?.- New Approaches in Locally Advanced NSCLC.- Advances in Radiotherapy for Locally Advanced NSCLC.- Advances in Systemic Treatment for Locally Advanced NSCLC.- Surgery of Advanced Tumors.- New Approaches in Stage IV NSCLC.- How to Personalize Chemotherapy in Stage IV NSCLC?.- Supportive Care.- Molecular Subgroups.- Strategies in EGFR Mutated NSCLC Patients.- Strategies in ALK Rearranged NSCLC patients.- Strategies in KRAS mutated NSCLC Patients.- Strategies in Patients with Other Molecular Alterations.- New Approaches in Immunotherapy.- Management of Particular Cases.- Oligometastasis.- Bone Metastasis.- Brain Metastasis.

Über Autor(innen)

Solange Peters, MD-PhD, PD-MER, is in charge of the thoracic malignancies program in the Department of Oncology of the University of Lausanne and active in building a translational program in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan as well as the Ludwig Institute. Her main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also heavily involved and interested in developing multimodality trials for locally advanced NSCLC. She is co-chair of the Swiss lung cancer research group (SAKK) and Scientific Coordinator as well as Chair of the Informatics Committee of the European Thoracic Oncology Platform (ETOP). She has been elected the Swiss national representative of ESMO in 2013. Dr Benjamin Besse is a cancer specialist, Head of the Thoracic Oncology Unit at the Institut Gustave Roussy in France. His main research interests are application of molecular abnormalities to personalize treatment, phase I trials in thoracic tumors and thymic tumors. He has been the main Investigator of more than 30 phase I and phase II trials in the past 5 years. He coordinates the French network for thymic malignancies. He is associate editor of European Respiratory Journal. He was the coordinating author for the ESMO Guidelines Working Group on Non-Small Cell Lung Cancer (NSCLC) and is Chair of the systemic treatment part of the 2013 ESMO Consensus Conference on Lung Cancer. He is member of the administrative board of the French Intergroup for Thoracic Oncology (IFCT) and Member of ASCO, ESMO and IASLC.